



Announcement Summary

Entity name

STARPHARMA HOLDINGS LIMITED

Date of this announcement

Wednesday December 17, 2025

The +securities the subject of this notification are:

+Other securities issued under an +employee incentive scheme that are not intended to be quoted on ASX

Total number of +securities to be issued/transferred

ASX +security code	Security description	Total number of +securities to be issued/transferred	Issue date
SPLAK	PERFORMANCE RIGHT	16,156,437	12/12/2025

Refer to next page for full details of the announcement



Part 1 - Entity and announcement details

1.1 Name of entity

STARPHARMA HOLDINGS LIMITED

We (the entity named above) give notice of the issue, conversion or payment up of the following unquoted +securities.

1.2 Registered number type

ABN

Registration number

20078532180

1.3 ASX issuer code

SPL

1.4 The announcement is

New announcement

1.5 Date of this announcement

17/12/2025



Part 2 - Issue details

2.1 The +securities the subject of this notification are:

+Other securities issued under an +employee incentive scheme that are not intended to be quoted on ASX

2.2a This notification is given in relation to an issue of +securities in a class which is not quoted on ASX and which:

has an existing ASX security code ("existing class")



Part 3B - number and type of +securities the subject of this notification (existing class) where issue has not previously been notified to ASX in an Appendix 3B

ASX +security code and description

SPLAK : PERFORMANCE RIGHT

Date the +securities the subject of this notification were issued

12/12/2025

Will these +securities rank equally in all respects from their issue date with the existing issued +securities in that class

Yes

Were any of the +securities issued to +key management personnel (KMP) or an +associate?

Yes

Provide details of the KMP or +associates being issued +securities.

Name of KMP	Name of registered holder	Number of +securities
Justin Cahill	Justin Cahill	650,000
Cheryl Maley	Cheryl Maley	6,525,939

Please provide a URL link for a document lodged with ASX detailing the terms of the +employee incentive scheme or a summary of the terms

<https://starpharma.com/assets/asxannouncements/2023%20SPL%20Notice%20of%20AGM%20and%20Proxy%20Form%20Final.pdf>

Any other information the entity wishes to provide about the +securities the subject of this notification

Issue of 3,231,288 short-term equity (Deferred STI equity, vesting 30 June 2027) and 12,925,149 long-term equity (LTI equity, vesting 30 September 2028) performance rights to employees and the CEO. The issued performance rights are subject to performance conditions, including Total Shareholder Return.

The rights issue to employees is within the maximum approved by shareholders at the 2023 AGM. The issue to the CEO, Cheryl Maley was approved by Shareholders at the 2025 AGM (Resolution 3).

Issue details

Number of +securities

16,156,437

Part 4 - +Securities on issue

Following the issue, conversion or payment up of the +securities the subject of this notification, the +securities of the entity will comprise:

The figures in parts 4.1 and 4.2 below are automatically generated and may not reflect the entity's current issued capital if other Appendix 2A, Appendix 3G or Appendix 3H forms are currently with ASX for processing.

4.1 Quoted +securities (Total number of each +class of +securities issued and quoted on ASX)

ASX +security code and description	Total number of +securities on issue
SPL : ORDINARY FULLY PAID	418,224,781

4.2 Unquoted +securities (Total number of each +class of +securities issued but not quoted on ASX)

ASX +security code and description	Total number of +securities on issue
SPLAK : PERFORMANCE RIGHT	44,877,771



Part 5 - Other Listing Rule requirements

5.1 Were the +securities issued under an exception in Listing Rule 7.2 and therefore the issue did not need any security holder approval under Listing Rule 7.1?

Yes

5.1a Select the number of the applicable exception in Listing Rule 7.2

13